Sr 9009 Magnus

Catalogue entry: Sr 9009 Magnus. Labelled content: 10 mg/tablet. Listed pack: 60 tablets. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

SR-9009 is a synthetic research compound initially described as a REV-ERB agonist. REV-ERB proteins participate in circadian and metabolic regulation. This is a different biological system from the androgen receptor, so SR-9009 is not a SARM despite its frequent placement in the same commercial category.

What the research measured

Solt and colleagues reported metabolic effects of synthetic REV-ERB ligands in animal experiments in Nature in 2012. Dierickx and colleagues later showed in PNAS in 2019 that important SR-9009 effects could occur independently of REV-ERB. That result makes a simple one-target explanation inadequate and matters when interpreting mechanism-led claims.

Sporting claims and limitations

Sporting promotion often emphasises energy expenditure or endurance. Neither target binding nor a mouse metabolic response establishes a useful human exercise effect. Cardarine acts through PPAR-delta and should not be treated as a mechanistic substitute. Human exposure, long-term toxicity and effects of combinations cannot be inferred from the cited experiments.

Product identity and documentation

The product option above records the supplier's labelled content and presentation. It does not convert an experimental probe into an established performance aid. Documentation should identify SR-9009 specifically, describe the analytical method and match the supplied lot. A generic certificate cannot establish oral performance effects or settle unresolved target specificity. Reliable identity is necessary for interpreting a sample, while it remains separate from evidence of clinical benefit.